Join
Live feed
·
INSIDERFilingvia Quantisnow
Akero Therapeutics Inc. logo

Chief Development Officer Yale Catriona was granted 890 shares, increasing direct ownership by 0.98% to 91,488 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
AKRO· Akero Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AKRO (Akero Therapeutics Inc.) and more on Quantisnow.